LONG FACTOR CERTIFICATE - UCB | Market Closed - Euronext Paris 17:30:02 07/06/2024 BST | ||
| 2,003 EUR | +3.37% |
|
| Current month | +14.45% | ||
| 1 month | +70.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
UCB
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 1,962 | +1.25% |
| 06/06/24 | 1,938 | +0.76% |
| 05/06/24 | 1,923 | +18.67% |
| 04/06/24 | 1,621 | +4.60% |
| 03/06/24 | 1,549 | -9.63% |
Real-time Euronext Paris
Last update June 07, 2024 at 05:30 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | UCB |
| Issuer | Goldman Sachs |
| Y571H | |
| ISIN | DE000GG0U4Y6 |
| Date issued | 07/12/2023 |
| Strike | 120 € |
| Maturity | Unlimited |
| Parity | 0.01 : 1 |
| Emission price | 25.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2,231 € |
|---|---|
| Lowest since issue | 12.42 € |
| Spread | 100 € |
| Spread % | 4.89% |
Company Profile
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
-
Consensus: UCB
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
130
EUR
Average target price
126.4
EUR
Spread / Average Target
-2.78%
- Stock Market
- Certificates
- Y571H Certificat
